Equillium, Inc. (EQ): R&D Expense
$12.84M
Year ended 2025-12-31
$8.58M
Trailing 12 months to 2026-06-30
-30.1%
3-year compound annual growth
-7.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.84M | -65.7% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $37.43M | +1.1% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $37.04M | -1.4% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $37.55M | +42.3% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $26.38M | +36.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $19.38M | +9.9% | 2022-03-23, From 2020-01-01 |
| 2019-12-31 | $17.64M | +256.9% | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | $4.94M | n/a | 2020-03-26, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Equillium, Inc. (EQ) | 2025-12-31 | $12.84M | -65.7% |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $18.15M | +40.5% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $18.01M | -23.8% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $3.13M | +138.5% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $19.03M | -15.7% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
Compare EQ, NVCT, TVRD, VBIO side by side · Screen every company in Pharmaceutical Preparations ↗